Novartis AG (NVS)
110.52
+1.17
(+1.07%)
USD |
NYSE |
Nov 04, 16:00
110.15
-0.37
(-0.33%)
After-Hours: 20:00
Novartis Enterprise Value: 237.38B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 237.38B |
| November 01, 2024 | 235.04B |
| October 31, 2024 | 233.14B |
| October 30, 2024 | 236.16B |
| October 29, 2024 | 237.40B |
| October 28, 2024 | 247.60B |
| October 25, 2024 | 243.92B |
| October 24, 2024 | 242.60B |
| October 23, 2024 | 244.48B |
| October 22, 2024 | 244.98B |
| October 21, 2024 | 247.80B |
| October 18, 2024 | 250.69B |
| October 17, 2024 | 249.35B |
| October 16, 2024 | 249.47B |
| October 15, 2024 | 248.78B |
| October 14, 2024 | 248.94B |
| October 11, 2024 | 248.78B |
| October 10, 2024 | 245.96B |
| October 09, 2024 | 247.62B |
| October 08, 2024 | 243.88B |
| October 07, 2024 | 244.06B |
| October 04, 2024 | 244.24B |
| October 03, 2024 | 243.88B |
| October 02, 2024 | 245.28B |
| October 01, 2024 | 245.44B |
| Date | Value |
|---|---|
| September 30, 2024 | 246.38B |
| September 27, 2024 | 252.99B |
| September 26, 2024 | 252.99B |
| September 25, 2024 | 254.65B |
| September 24, 2024 | 254.63B |
| September 23, 2024 | 254.53B |
| September 20, 2024 | 253.66B |
| September 19, 2024 | 253.74B |
| September 18, 2024 | 253.72B |
| September 17, 2024 | 253.17B |
| September 16, 2024 | 255.70B |
| September 13, 2024 | 253.09B |
| September 12, 2024 | 253.21B |
| September 11, 2024 | 252.32B |
| September 10, 2024 | 255.78B |
| September 09, 2024 | 256.13B |
| September 06, 2024 | 255.10B |
| September 05, 2024 | 254.77B |
| September 04, 2024 | 260.62B |
| September 03, 2024 | 258.84B |
| August 30, 2024 | 263.68B |
| August 29, 2024 | 262.73B |
| August 28, 2024 | 261.84B |
| August 27, 2024 | 261.55B |
| August 26, 2024 | 260.16B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
161.05B
Minimum
Oct 12 2022
263.68B
Maximum
Aug 30 2024
209.22B
Average
212.59B
Median
Sep 30 2020
Enterprise Value Benchmarks
| Amgen Inc | 221.77B |
| AstraZeneca PLC | 246.74B |
| Johnson & Johnson | 396.44B |
| Eli Lilly and Co | 792.96B |
| Merck & Co Inc | 284.72B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.189B |
| Revenue (Quarterly) | 13.17B |
| Total Expenses (Quarterly) | 9.545B |
| EPS Diluted (Quarterly) | 1.57 |
| Gross Profit Margin (Quarterly) | 75.45% |
| Profit Margin (Quarterly) | 24.21% |
| Earnings Yield | 7.72% |
| Operating Earnings Yield | 6.00% |
| Normalized Earnings Yield | 5.194 |